NASDAQ:AVXL - Anavex Life Sciences Stock Price, Price Target & More

$2.37 +0.09 (+3.95 %)
(As of 04/23/2018 01:06 PM ET)
Previous Close$2.28
Today's Range$2.30 - $2.49
52-Week Range$1.85 - $6.27
Volume290,177 shs
Average Volume308,984 shs
Market Capitalization$101.63 million
P/E Ratio-7.18
Dividend YieldN/A
Beta0.87

About Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences logoAnavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, which has completed Phase IIa clinical trials for the treatment of Alzheimer's disease; and in preclinical clinical trials to treat Parkinson's disease, epilepsy, Rett syndrome, Angelman syndrome, multiple sclerosis, and Fragile X syndrome. Its preclinical drug candidates include ANAVEX 3-71 to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York.

Receive AVXL News and Ratings via Email

Sign-up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AVXL
CUSIPN/A
Phone844-689-3939

Debt

Debt-to-Equity RatioN/A
Current Ratio10.14%
Quick Ratio10.14%

Price-To-Earnings

Trailing P/E Ratio-7.18
Forward P/E Ratio-5.78
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.58 per share
Price / Book4.09

Profitability

EPS (Most Recent Fiscal Year)($0.33)
Net Income$-13,460,000.00
Net MarginsN/A
Return on Equity-69.24%
Return on Assets-62.66%

Miscellaneous

Employees10
Outstanding Shares44,570,000

How to Become a New Pot Stock Millionaire

Anavex Life Sciences (NASDAQ:AVXL) Frequently Asked Questions

What is Anavex Life Sciences' stock symbol?

Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL."

How were Anavex Life Sciences' earnings last quarter?

Anavex Life Sciences (NASDAQ:AVXL) announced its earnings results on Wednesday, February, 7th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter. View Anavex Life Sciences' Earnings History.

When is Anavex Life Sciences' next earnings date?

Anavex Life Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Anavex Life Sciences.

What price target have analysts set for AVXL?

3 brokers have issued 12 month price objectives for Anavex Life Sciences' stock. Their forecasts range from $5.00 to $15.00. On average, they anticipate Anavex Life Sciences' share price to reach $8.6667 in the next twelve months. View Analyst Ratings for Anavex Life Sciences.

What are Wall Street analysts saying about Anavex Life Sciences stock?

Here are some recent quotes from research analysts about Anavex Life Sciences stock:
  • 1. According to Zacks Investment Research, "ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways. " (4/10/2018)
  • 2. Maxim Group analysts commented, "We have increased our therapeutic rate cut in our model to 90%, from 75% – taking our price target to $5, from $14, which is still substantially higher versus the current stock price – due to a combination of factors which include: ○ The trial was delayed (biomarkers) and will take time and money. While the company has $28M in capital today, we believe a lot more capital will be needed as the next phases of clinical development get underway, ○ When will we see meaningful clinical data that can convince both KOL’s and Industry experts that the company may have a drug? It will take time." (2/8/2018)

Who are some of Anavex Life Sciences' key competitors?

Who are Anavex Life Sciences' key executives?

Anavex Life Sciences' management team includes the folowing people:
  • Dr. Christopher U. Missling, Chairman, Pres, CEO & Sec. (Age 52)
  • Ms. Sandra Boenisch, Principal Financial Officer & Treasurer (Age 37)
  • Mr. Stephan Toutain, Sr. VP of Operations (Age 52)
  • Dr. Emmanuel O. Fadiran RPh, Ph.D., Sr. VP of Regulatory Affairs
  • Dr. Tasos Zografidis M.S., Ph.D., VP of Clinical Operations

Has Anavex Life Sciences been receiving favorable news coverage?

Press coverage about AVXL stock has trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Anavex Life Sciences earned a news impact score of 0.09 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.32 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Anavex Life Sciences?

Shares of AVXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anavex Life Sciences' stock price today?

One share of AVXL stock can currently be purchased for approximately $2.37.

How big of a company is Anavex Life Sciences?

Anavex Life Sciences has a market capitalization of $101.63 million. The biotechnology company earns $-13,460,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Anavex Life Sciences employs 10 workers across the globe.

How can I contact Anavex Life Sciences?

Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 844-689-3939 or via email at [email protected]


MarketBeat Community Rating for Anavex Life Sciences (AVXL)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  206 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  305
MarketBeat's community ratings are surveys of what our community members think about Anavex Life Sciences and other stocks. Vote "Outperform" if you believe AVXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVXL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Anavex Life Sciences (NASDAQ:AVXL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Anavex Life Sciences in the last 12 months. Their average twelve-month price target is $8.6667, suggesting that the stock has a possible upside of 265.68%. The high price target for AVXL is $15.00 and the low price target for AVXL is $5.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.6667$8.6667$14.50$15.00
Price Target Upside: 265.68% upside176.01% upside330.41% upside273.13% upside

Anavex Life Sciences (NASDAQ:AVXL) Consensus Price Target History

Price Target History for Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences (NASDAQ:AVXL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/8/2018Roth CapitalInitiated CoverageBuy -> Buy$6.00HighView Rating Details
2/21/2018Noble FinancialReiterated RatingBuyLowView Rating Details
2/14/2018Maxim GroupSet Price TargetBuy$5.00LowView Rating Details
10/5/2016FBR & CoReiterated RatingOutperform$10.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Anavex Life Sciences (NASDAQ:AVXL) Earnings History and Estimates Chart

Earnings by Quarter for Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences (NASDAQ:AVXL) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.41 EPS
Next Year EPS Consensus Estimate: $-0.48 EPS

Anavex Life Sciences (NASDAQ AVXL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018        
2/7/2018Q1 2018($0.09)ViewN/AView Earnings Details
12/11/2017Q4 2017($0.10)($0.12)ViewListenView Earnings Details
8/7/2017Q3 2017($0.09)($0.09)ViewN/AView Earnings Details
5/10/2017Q2 2017($0.09)($0.09)ViewN/AView Earnings Details
2/7/2017Q1 2017($0.0820)ViewN/AView Earnings Details
12/12/2016Q4 2016($0.08)($0.18)ViewN/AView Earnings Details
8/11/2016Q316($0.09)($0.06)ViewN/AView Earnings Details
5/11/2016Q2($0.16)($0.06)ViewN/AView Earnings Details
2/8/2016Q116($0.12)ViewN/AView Earnings Details
12/29/2015Q4 2015($0.54)ViewN/AView Earnings Details
8/17/2015Q3 2015($0.08)ViewN/AView Earnings Details
5/15/2015Q2 2015($0.12)ViewN/AView Earnings Details
2/18/2015Q1 2015($0.08)ViewN/AView Earnings Details
12/30/2014Q4 2014($0.96)ViewN/AView Earnings Details
8/13/2014Q3 2014($0.12)ViewN/AView Earnings Details
5/15/2014Q2 2014($0.12)ViewN/AView Earnings Details
2/14/2013Q1 2013($0.04)ViewN/AView Earnings Details
12/22/2011Q4 2011($0.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Anavex Life Sciences (NASDAQ:AVXL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Anavex Life Sciences (NASDAQ AVXL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.10%
Institutional Ownership Percentage: 22.70%
Insider Trading History for Anavex Life Sciences (NASDAQ:AVXL)
Insider Trading History for Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences (NASDAQ AVXL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/7/2018Christopher U MisslingInsiderBuy1,360$2.92$3,971.20View SEC Filing  
3/5/2018Christopher U MisslingCEOBuy1,500$2.63$3,945.001,015,400View SEC Filing  
3/2/2018Christopher U MisslingCEOBuy1,650$2.41$3,976.501,013,900View SEC Filing  
10/24/2017Christopher U MisslingCEOBuy375$4.92$1,845.001,011,875View SEC Filing  
10/19/2017Christopher U MisslingInsiderBuy375$4.49$1,683.751,011,500View SEC Filing  
10/17/2017Christopher U MisslingInsiderBuy375$4.27$1,601.25View SEC Filing  
10/13/2017Christopher U MisslingInsiderBuy750$4.22$3,165.00View SEC Filing  
10/5/2017Christopher U MisslingInsiderBuy375$4.30$1,612.50View SEC Filing  
10/2/2017Christopher U MisslingInsiderBuy375$4.20$1,575.001,009,625View SEC Filing  
9/28/2017Christopher U MisslingInsiderBuy375$4.21$1,578.751,009,250View SEC Filing  
9/26/2017Christopher U MisslingInsiderBuy375$3.88$1,455.001,008,875View SEC Filing  
9/20/2017Christopher U MisslingInsiderBuy375$4.23$1,586.251,008,500View SEC Filing  
9/18/2017Christopher U MisslingInsiderBuy375$4.40$1,650.001,008,125View SEC Filing  
9/14/2017Christopher U MisslingInsiderBuy375$4.58$1,717.501,007,750View SEC Filing  
9/11/2017Christopher U MisslingInsiderBuy375$4.81$1,803.751,007,375View SEC Filing  
9/7/2017Christopher U MisslingInsiderBuy375$4.76$1,785.001,007,000View SEC Filing  
9/5/2017Christopher U MisslingInsiderBuy375$4.90$1,837.501,006,625View SEC Filing  
8/31/2017Christopher U MisslingInsiderBuy375$4.48$1,680.001,006,250View SEC Filing  
8/28/2017Christopher U MisslingInsiderBuy375$4.44$1,665.001,005,875View SEC Filing  
8/24/2017Christopher U MisslingInsiderBuy375$4.54$1,702.501,005,500View SEC Filing  
8/21/2017Christopher U MisslingInsiderBuy375$4.07$1,526.251,005,125View SEC Filing  
8/18/2017Christopher U MisslingInsiderBuy375$3.81$1,428.751,004,750View SEC Filing  
8/14/2017Christopher U MisslingInsiderBuy375$3.70$1,387.501,004,375View SEC Filing  
8/11/2017Christopher U MisslingInsiderBuy750$3.55$2,662.501,004,000View SEC Filing  
7/14/2015Christopher U MisslingCEOBuy1,000$0.52$520.00View SEC Filing  
7/13/2015Christopher U MisslingCEOBuy1,000$0.53$530.00View SEC Filing  
7/7/2015Christopher U MisslingCEOBuy2,000$0.49$980.00View SEC Filing  
7/1/2015Christopher U MisslingCEOBuy2,000$0.45$900.00View SEC Filing  
6/23/2015Christopher U MisslingCEOBuy1,000$0.47$470.00View SEC Filing  
6/22/2015Christopher U MisslingCEOBuy1,000$0.42$420.00View SEC Filing  
6/16/2015Christopher U MisslingCEOBuy1,000$0.44$440.00View SEC Filing  
6/15/2015Christopher U MisslingCEOBuy1,000$0.43$430.00View SEC Filing  
6/10/2015Christopher U MisslingCEOBuy1,000$0.36$360.00View SEC Filing  
6/8/2015Christopher U MisslingCEOBuy1,000$0.35$350.00View SEC Filing  
6/4/2015Christopher U MisslingCEOBuy1,000$0.37$370.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Anavex Life Sciences (NASDAQ AVXL) News Headlines

Source:
DateHeadline
Active-Investors: Wired News - Anavex Life Sciences To Commence Phase-2 Study of ANAVEX(R)2-73 in Parkinsons Disease DementiaActive-Investors: Wired News - Anavex Life Sciences To Commence Phase-2 Study of ANAVEX(R)2-73 in Parkinson's Disease Dementia
www.finanznachrichten.de - April 19 at 9:32 AM
Wired News – Anavex Life Sciences To Commence Phase-2 Study of ANAVEX(R)2-73 in Parkinson’s Disease DementiaWired News – Anavex Life Sciences To Commence Phase-2 Study of ANAVEX(R)2-73 in Parkinson’s Disease Dementia
finance.yahoo.com - April 19 at 9:32 AM
Anavex Life Sciences Corp. (AVXL) Expected to Post Earnings of -$0.10 Per ShareAnavex Life Sciences Corp. (AVXL) Expected to Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - April 17 at 1:17 PM
Anavex Life Sciences (AVXL) Raised to Hold at ValuEngineAnavex Life Sciences (AVXL) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 13 at 1:35 PM
Anavex Life Sciences (AVXL) Upgraded at Zacks Investment ResearchAnavex Life Sciences (AVXL) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 10 at 8:28 AM
Edited Transcript of AVXL earnings conference call or presentation 7-Feb-18 9:30pm GMTEdited Transcript of AVXL earnings conference call or presentation 7-Feb-18 9:30pm GMT
finance.yahoo.com - April 1 at 9:19 AM
Zacks: Anavex Life Sciences Corp. (AVXL) Given Consensus Rating of "Strong Buy" by AnalystsZacks: Anavex Life Sciences Corp. (AVXL) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - April 1 at 1:26 AM
Zacks: Analysts Anticipate Anavex Life Sciences Corp. (AVXL) Will Post Earnings of -$0.10 Per ShareZacks: Analysts Anticipate Anavex Life Sciences Corp. (AVXL) Will Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - March 31 at 3:14 PM
Anavex Life Sciences (AVXL) Downgraded by Zacks Investment ResearchAnavex Life Sciences (AVXL) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 23 at 6:07 PM
Anavex Life Sciences (AVXL) Lifted to Buy at Zacks Investment ResearchAnavex Life Sciences (AVXL) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - March 22 at 5:49 PM
Reviewing Medgenics (GNMX) and Anavex Life Sciences (AVXL)Reviewing Medgenics (GNMX) and Anavex Life Sciences (AVXL)
www.americanbankingnews.com - March 13 at 1:18 AM
Anavex Life Sciences to Present at the 30th Annual ROTH ConferenceAnavex Life Sciences to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 9 at 10:59 AM
Anavex Life Sciences (AVXL) Coverage Initiated by Analysts at Roth CapitalAnavex Life Sciences (AVXL) Coverage Initiated by Analysts at Roth Capital
www.americanbankingnews.com - March 8 at 10:37 AM
Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for ... - GlobeNewswire (press release)Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for ... - GlobeNewswire (press release)
globenewswire.com - March 7 at 4:42 PM
Anavex Life Sciences Strengthens Management Team and Board of Directors - GlobeNewswire (press release)Anavex Life Sciences Strengthens Management Team and Board of Directors - GlobeNewswire (press release)
globenewswire.com - March 7 at 4:42 PM
44 Biggest Movers From Yesterday | Benzinga - Benzinga44 Biggest Movers From Yesterday | Benzinga - Benzinga
www.benzinga.com - March 7 at 4:42 PM
Anavex Life Sciences to Present at Cowen and Company 38th Annual Health Care Conference - GlobeNewswire (press release)Anavex Life Sciences to Present at Cowen and Company 38th Annual Health Care Conference - GlobeNewswire (press release)
globenewswire.com - March 7 at 4:42 PM
Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)
finance.yahoo.com - March 7 at 9:49 AM
Anavex Life Sciences to Present at Cowen and Company 38th Annual Health Care ConferenceAnavex Life Sciences to Present at Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 9:34 AM
Anavex Life Sciences Strengthens Management Team and Board of DirectorsAnavex Life Sciences Strengthens Management Team and Board of Directors
finance.yahoo.com - March 5 at 10:22 AM
Anavex Life Sciences (AVXL) "Buy" Rating Reaffirmed at Noble FinancialAnavex Life Sciences' (AVXL) "Buy" Rating Reaffirmed at Noble Financial
www.americanbankingnews.com - February 21 at 8:16 PM
Sevion Therapeutics (SVON) & Anavex Life Sciences (AVXL) Head to Head ReviewSevion Therapeutics (SVON) & Anavex Life Sciences (AVXL) Head to Head Review
www.americanbankingnews.com - February 20 at 7:08 PM
Anavex Life Sciences (AVXL) PT Set at $5.00 by Maxim GroupAnavex Life Sciences (AVXL) PT Set at $5.00 by Maxim Group
www.americanbankingnews.com - February 18 at 5:54 PM
Anavex Life Sciences (AVXL) Presents At BIO CEO & Investor Conference - SlideshowAnavex Life Sciences (AVXL) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 14 at 3:26 PM
Anavexs (AVXL) CEO Christopher Missling on Q1 2018 Results ... - Seeking AlphaAnavex's (AVXL) CEO Christopher Missling on Q1 2018 Results ... - Seeking Alpha
seekingalpha.com - February 9 at 6:37 AM
Anavex Life Sciences to Present at the 2018 BIO CEO & Investor Conference - GlobeNewswire (press release)Anavex Life Sciences to Present at the 2018 BIO CEO & Investor Conference - GlobeNewswire (press release)
globenewswire.com - February 9 at 6:37 AM
Maxim Group Analysts Give Anavex Life Sciences (AVXL) a $14.00 Price TargetMaxim Group Analysts Give Anavex Life Sciences (AVXL) a $14.00 Price Target
www.americanbankingnews.com - February 8 at 9:28 PM
Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial ResultsAnavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results
finance.yahoo.com - February 8 at 3:24 PM
Anavex Life Sciences to Present at the 2018 BIO CEO & Investor ConferenceAnavex Life Sciences to Present at the 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 8 at 3:24 PM
Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results - GlobeNewswire (press release)Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results - GlobeNewswire (press release)
globenewswire.com - February 8 at 6:27 AM
Anavex Life Sciences to Announce Fiscal First Quarter 2018 Financial Results and Provide an Update on Clinical ... - GlobeNewswire (press release)Anavex Life Sciences to Announce Fiscal First Quarter 2018 Financial Results and Provide an Update on Clinical ... - GlobeNewswire (press release)
globenewswire.com - February 5 at 3:23 PM
Anavex And Alzheimers Disease At The Crossroads - Seeking AlphaAnavex And Alzheimer's Disease At The Crossroads - Seeking Alpha
seekingalpha.com - January 30 at 3:24 PM
Anavex Life Sciences to Present at the Noble Capital Markets 14th ... - GlobeNewswire (press release)Anavex Life Sciences to Present at the Noble Capital Markets 14th ... - GlobeNewswire (press release)
globenewswire.com - January 24 at 3:27 PM
Anavex Life Sciences to Present at the Noble Capital Markets 14th Annual Institutional Investor ConferenceAnavex Life Sciences to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference
finance.yahoo.com - January 24 at 9:52 AM
Anavex Life Sciences Reports Potential Normalization of ... - GlobeNewswire (press release)Anavex Life Sciences Reports Potential Normalization of ... - GlobeNewswire (press release)
globenewswire.com - January 16 at 11:27 AM
Jazz Pharmaceuticals (JAZZ) vs. Anavex Life Sciences (AVXL) Head-To-Head ComparisonJazz Pharmaceuticals (JAZZ) vs. Anavex Life Sciences (AVXL) Head-To-Head Comparison
www.americanbankingnews.com - December 18 at 11:34 PM
Edited Transcript of AVXL earnings conference call or presentation 11-Dec-17 9:30pm GMTEdited Transcript of AVXL earnings conference call or presentation 11-Dec-17 9:30pm GMT
finance.yahoo.com - December 13 at 3:40 PM
Noble Financial Reaffirms Buy Rating for Anavex Life Sciences (AVXL)Noble Financial Reaffirms Buy Rating for Anavex Life Sciences (AVXL)
www.americanbankingnews.com - December 13 at 3:34 PM
Head-To-Head Comparison: Tetralogic Pharmaceuticals (TLOG) versus Anavex Life Sciences (AVXL)Head-To-Head Comparison: Tetralogic Pharmaceuticals (TLOG) versus Anavex Life Sciences (AVXL)
www.americanbankingnews.com - December 13 at 1:36 PM
Head to Head Analysis: Anavex Life Sciences (AVXL) and Osiris Therapeutics (OSIR)Head to Head Analysis: Anavex Life Sciences (AVXL) and Osiris Therapeutics (OSIR)
www.americanbankingnews.com - December 13 at 9:26 AM
Critical Analysis: Anavex Life Sciences (AVXL) & Tetralogic Pharmaceuticals (TLOG)Critical Analysis: Anavex Life Sciences (AVXL) & Tetralogic Pharmaceuticals (TLOG)
www.americanbankingnews.com - December 13 at 3:50 AM
42 Biggest Movers From Yesterday | Benzinga - Benzinga42 Biggest Movers From Yesterday | Benzinga - Benzinga
www.benzinga.com - December 12 at 12:03 PM
Anavex Life Sciences (AVXL) Releases  Earnings ResultsAnavex Life Sciences (AVXL) Releases Earnings Results
www.americanbankingnews.com - December 12 at 9:26 AM
Anavex Life Sciences (AVXL) vs. Grifols SA, Barcelona (GRFS) Head to Head AnalysisAnavex Life Sciences (AVXL) vs. Grifols SA, Barcelona (GRFS) Head to Head Analysis
www.americanbankingnews.com - December 11 at 6:26 PM
Anavex Life Sciences (AVXL) PT Set at $14.00 by Maxim GroupAnavex Life Sciences (AVXL) PT Set at $14.00 by Maxim Group
www.americanbankingnews.com - December 11 at 5:08 PM
Zacks: Anavex Life Sciences Corp. (AVXL) Given Average Rating of "Strong Buy" by AnalystsZacks: Anavex Life Sciences Corp. (AVXL) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - December 5 at 11:30 AM
Critical Review: Windtree Therapeutics (WINT) vs. Anavex Life Sciences (AVXL)Critical Review: Windtree Therapeutics (WINT) vs. Anavex Life Sciences (AVXL)
www.americanbankingnews.com - December 5 at 5:28 AM
Critical Analysis: Anavex Life Sciences (AVXL) vs. Mirati Therapeutics (MRTX)Critical Analysis: Anavex Life Sciences (AVXL) vs. Mirati Therapeutics (MRTX)
www.americanbankingnews.com - December 4 at 8:44 AM
Anavex Life Sciences (AVXL) Scheduled to Post Quarterly Earnings on MondayAnavex Life Sciences (AVXL) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - December 4 at 1:38 AM
Anavex Life Sciences Corp. (AVXL) Expected to Announce Earnings of -$0.10 Per ShareAnavex Life Sciences Corp. (AVXL) Expected to Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - December 2 at 1:38 PM

SEC Filings

Anavex Life Sciences (NASDAQ:AVXL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Anavex Life Sciences (NASDAQ:AVXL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Anavex Life Sciences (NASDAQ AVXL) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.